Aclaris plans common stock offering

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
WebinarPractical steps to achieve net-zero underwriting – Set a baseline, define targets and take action
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am GMT
WebinarPolitics & Policy: Sustainability Measures and Physical Risks
- 03/30/2023
- Live, Online
- 10:00 am - 11:00 am EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in

Blog

A Cloud Migration Plan for Corporations featuring Snowflake®

Blog

Investor Activism Campaigns Hit Record High in 2022

Blog

Essential IR Insights Newsletter - February 2023

9 Aug, 2017 | 19:38

Author Mirza Salam Ahmed
Theme Healthcare & Pharmaceuticals

Aclaris Therapeutics Inc. plans to sell up to $75 million of its common stock in an underwritten public offering.

The company will grant underwriters an option to buy up to an additional $11.3 million of common stock.

Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. William Blair & Co. LLC, Guggenheim Securities LLC, and JMP Securities LLC are acting as co-managers for the offering.